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The administration of chemotherapy has allowed improvement of
survival in comparison to best supportive care alone (Grilli et al,
1993; Souquet et al, 1993; Marino et al, 1994; Sculier et al, 1999a)
in metastatic non-small cell lung cancer (NSCLC). Moreover,
it was also found to be associated with a better quality of
life (Thongprasert et al, 1999) and a reduced economic cost
(Jaakkimainen et al, 1990). The classical active cytostatic agents
for NSCLC are cisplatin, mitomycin, vindesine, vinblastine and
ifosfamide (Donnadlieu et al, 1991). New active drugs recently
introduced are paclitaxel, docetaxel, gemcitabine and vinorelbine
(Meert et al, 1999).
Cisplatin is considered so far to be the most important drug. A
series of randomized trials (Fuks et al, 1983; Elliott et al, 1984;
Robert et al, 1984; Einhorn et al, 1986; Luedke et al, 1990; Rosso et
al, 1990; Depierre et al, 1994; Le Chevalier et al, 1994) have shown
that the addition of cisplatin to a combination of other cytostatic
agents improves the objective response rates in the majority of the
studies and prolongs survival with a statistically significant compar-
ison test in half of them. The dosage of cisplatin has been investi-
gated in four randomized trials (Gralla et al, 1981; Klastersky et al,
1986; Shinkai et al, 1986; Gandara et al, 1993). Two of them
included very small numbers of patients. When combined with
etoposide or vindesine, there seems to be no advantage in terms of
response or survival to administer high cisplatin doses (120 mg m–2)
in comparison to moderate doses (60 or 80 mg m–2).
A major issue with the higher doses of cisplatin is delayed
toxicity: our Group (see Appendix) has shown (Sculier et al,
1994a) that the risk of developing a WHO Grade II neurological
(polyneuropathy), auditory (hypoacousia) or renal (renal failure)
toxicity, after six courses of high-dose cisplatin (120 mg m–2), is
about 25%. This toxicity precludes further therapy and probably
reduces the impact of cisplatin therapy on survival. Replacement
of cisplatin by its better-tolerated analogue, carboplatin, has been
disappointing because it induces less favourable results, at least in
terms of response rate (Klastersky et al, 1990). But, if moderate
dosages of carboplatin (200 mg m–2) and cisplatin (60 mg m–2) are
combined (Sculier et al, 1994a), the same activity as high doses of
cisplatin (120 mg m–2) is maintained in terms of response and
survival with a reduced risk of long-term renal, neurological or
auditory toxicity (6% at six courses of therapy). In this regimen,
100 mg m–2 of carboplatin is considered equivalent to 30 mg m–2
of cisplatin. As previously discussed (Sculier et al, 1994a), this
equivalence is extrapolated from experimental data, no clinical
data being available.
The primary purpose of the present trial is to determine if, in
patients with stage IV NSCLC, the combination of moderate
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Summary A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin
(6 mg m–2) and ifosfamide (3 g m–2), the combination of moderate dosages of cisplatin (60 mg m–2) and carboplatin (200 mg m–2) – CarboMIP
regimen – improved survival in comparison with cisplatin (50 mg m–2) alone – MIP regimen. A total of 305 patients with no prior chemotherapy
were randomized, including 297 patients assessable for survival (147 in the MIP arm and 150 in the CarboMIP arm) and 268 patients
assessable for response to chemotherapy. All but eight (with malignant pleural effusion) had stage IV disease. There was a 27% (95% CI,
19–34) objective response (OR) rate to MIP (25% of the eligible patients) and a 33% (95% CI, 24–41) OR rate to CarboMIP (29% of the
eligible patients). This difference was not statistically significant (P = 0.34). Duration of response was not significantly different between both
arms. There was also no difference (P = 0.67) in survival: median survival times were 28 weeks (95% Cl, 24–32) for MIP and 32 weeks (95%
Cl, 26–35) for CarboMIP, with respectively 1-year survival rates of 24% and 23% and 2-year survival rates of 5% and 2%. The main toxicities
consisted in emesis, alopecia, leucopenia and thrombocytopenia, that were, except alopecia, significantly more severe in the CarboMIP arm.
Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in
addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of
cisplatin alone. The results support the use of a moderate dose (50 mg m–2) of cisplatin in combination with ifosfamide and mitomycin for the
chemotherapy of this disease. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1413, available online at http://www.idealibrary.com on dosages of cisplatin and carboplatin improves survival in compar-
ison with cisplatin alone in association with mitomycin and
ifosfamide as used in the Cullen regimen (Cullen et al, 1988).
PATIENTS AND METHODS
Selection criteria
Patients with histologically proven NSCLC had to fulfil all the
following criteria to enter this study: inoperable stage IV or stage
IIIB with malignant pleural effusion; presence of a measurable or
assessable lesion; no prior history of malignancy except non-
melanoma skin cancer, in situ carcinoma of the cervix or ‘cured’
malignant tumour (more than 5-year disease-free survival); no
prior chemotherapy; Karnofsky performance status (PS) ≥ 60;
good renal (serum creatinine level ≤ 1.5 mg dl–1 and/or creatinine
clearance ≥ 60 ml min–1), hepatic (serum bilirubin level ≤ 1.5 mg
dl–1) and haematological (WBC count ≥ 4000 mm–3 and platelet
count ≥ 100 000 mm–3) functions; no recent (less than 3 months
before the date of treatment) myocardial infarction and no active
congestive heart failure or cardiac arrhythmia requiring medical
treatment; no uncontrolled infectious disease; no other serious
medical or psychological factors which may prevent adherence to
the treatment schedule. Patients had to be accessible for follow-up
and had to provide informed consent. Protocol had to have been
approved by the local ethical committee of the investigator.
Treatment
Eligible patients were randomized between two arms: the
CarboMIP regimen consisting of moderate doses of a combination
of cisplatin (CDDP) (60 mg m–2) and carboplatin (CBDCA)
(200 mg m–2 plus mitomycin C (6 mg m–2) and ifosfamide (3 g
m–2) and the MIP regimen consisting of moderate doses of
cisplatin (50 mg m–2) plus mitomycin C and ifosfamide (same
dosages as in the CarboMIP regimen).
All drugs were given i.v. on day 1 of the cycle. Mitomycin C
was given as a bolus followed by ifosfamide infused over 3 h.
Cisplatin (Platinol®) was administered over 1 h, 3 h after the end
of the ifosfamide infusion. Mesna (Uromitexan®) (1 g m–2 3 h infu-
sion together with ifosfamide (Holoxan®), followed by 500 mg m–2
bolus at 4 and 8 h) was provided to avoid urotoxicity, according to
the initial Cullen publication (Cullen et al, 1988). Carboplatin
(Paraplatin®) was administered in ready-to-use solution over
30 min just before cisplatin infusion. Platinum derivatives admin-
istration was followed by i.v. infusion of 2000 ml NaCl 0.9% with
3 g KCl over 16 h. To control emesis, the administration of a
5-HT3 antagonist (granisetron) was recommended in combination
with dexamethasone and/or lorazepam.
Courses were given every 3 weeks. Tumour response was
assessed after three full courses. In case of stable disease or
progression, the treatment was discontinued. Responding patients
were given additional courses until best response, progression
(PG) or major toxicity.
Courses were repeated as soon as haematological (WBC
> 4000 mm–3 and platelets > 100 000 mm–3) and renal (serum
creatinine < 1.5 mg dl–1) functions had recovered. If delay between
two courses was more than 5 weeks, patient went off-treatment. If
WBC nadir was < 1000 mm–3 and/or platelet nadir < 25 000 mm–3,
carboplatin, ifosfamide and mitomycin C dosage were reduced to
75% during the following courses. If serum creatinine peak
increased between 1.5 and 3.0 mg dl–1, cisplatin dosage was
reduced to 50%. If it was > 3.0 mg dl–1, cisplatin was stopped. In
case of occurrence of hearing loss or > WHO grade II neurotoxi-
city, cisplatin was also stopped.
Investigations
The initial work-up consisted of complete history and physical
examination with weight, height and surface-area measurements;
recording of performance status; fibreoptic bronchoscopy with
biopsy; bone scintigraphy; liver and adrenals computed tomog-
raphy (CT) scan or echography; brain CT scan; blood chemistries
including complete blood-cell count, electrolytes, serum creatinine
and liver function tests; EKG.
Blood chemistries, chest X-ray, and clinical examination were
repeated before each course. Restaging with all tests performed
during the initial work-up was repeated after the first three courses
and every three courses if treatment was continued.
After treatment completion, patients were followed up every
2 months for the first 6 months and then every 3 months, with
clinical examination, chest X-rays and biological tests.
Criteria of evaluation
Patients were evaluated for response after completion of three
courses of chemotherapy. Responses were evaluated by at least
three independent observers during regular meetings of the Group.
Complete remission (CR) was defined as the disappearance of all
signs of disease, for at least 4 weeks. Partial response (PR), in
measurable disease, consisted of 50% or greater decrease of the
total tumour load as established by two observations not less than
4 weeks apart and without the appearance of new lesions or
progression of any lesion. The tumour load was estimated as the
tumour area calculated by the multiplication of the longest diam-
eter by the greatest perpendicular diameter. In assessable disease,
PR was defined as an estimated decrease in tumour size of 50% or
more. PG was considered to be an increase of greater than 25% in
one or more measurable or assessable lesions or the appearance of
a new lesion. All other circumstances were classified as no change
(NC). Patients with early death (ED) due to disease progression
before evaluation, those with toxic death due to chemotherapy,
or those with early chemotherapy stoppage for toxicity, were
considered as treatment failures.
Duration of response was calculated from the day of registration
until the date of the first observation of PG. Survival was dated
from the day of registration. WHO criteria were used to assess
toxicity.
Primary endpoint and sample-size determination
The primary objective of the trial was to compare the survival
distributions obtained with the MIP and CarboMIP regimens. The
sample-size evaluation was based on this endpoint. On the basis
of the Group’s previous experience, for the MIP regimen we
expected a 1-year survival rate of 20%. It was judged that an
improvement of this rate from 20–35% would be clinically mean-
ingful. With these assumptions and using a two-sided logrank test
for the primary comparison of the two arms of the study (α = 5%,
β = 20%), 123 eligible patients needed to be randomized in each
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deaths in each group. As there were no formal data on the toxicity
of the CarboMIP combination, an interim analysis on the tolerance
of the regimen was performed after evaluation of the first 20
randomized patients. No interim analysis for survival was planned
or performed.
Randomization procedure
Randomization was centrally performed using the minimization
technique and stratified according to centre, presence of brain
metastases, existence of prior chest irradiation and Karnofsky
performance status. Treatment allocation was obtained by calling
the ELCWP data center.
Statistical methodology
Survival curves were estimated by the method of Kaplan and
Meier. The log-rank test was used to compare survival curves. P-
values for testing differences between proportions were calculated
with Chi-square tests or with Fisher’s exact tests. A multivariate
analysis for comparison adjustment taking into account prognostic
factors was performed by fitting the data with a Cox model for
duration of survival and a logistic regression model for objective
response.
The evaluation of chemotherapy intensity was performed by
calculating absolute and relative dose intensities. The absolute
dose intensity (ADI) was defined as the ratio of the received dose
per m–2 body surface to the actual duration of treatment: it is
expressed in mg m–2 week–1. Carboplatin was considered equiva-
lent to cisplatin in the ratio 100/30. All the formulas have been
previously published (Sculier et al, 1996). Comparisons of the
distributions of the dose intensity variables between regimens
have been done by using the Mann–Whitney test.
The influence of the modality of prescription of carboplatin
according to the body surface or to the carboplatin clearance
related to the renal function was evaluated according to the Calvert
AUC-based equation. As creatinine clearance was not systemati-
cally available, glomerular filtration rate (GFR) was evaluated
according to the Cockcroft formula, from serum creatinine that
was measured before each new cycle of chemotherapy. The
method reported by Chatelut was also used to calculate the carbo-
platin clearance according to weight, age, sex and serum creati-
nine. All the formulas and references have been reported in a prior
publication (Sculier et al, 1999b).
RESULTS
Patient population and characteristics
A total of 305 patients were randomized between October 1995 and
March 1998. Eight (2.6%) were ineligible for the study (five on the
MIP arm and three on the CarboMIP arm) for the following reasons:
no assessable lesion (n = 5), presence of a second active cancer (n =
2), patient inaccessible to follow-up (n = 1). Among the 297 patients
assessable for survival, 29 (9.8%) were not assessable for response
(11 on the MIP arm and 18 on the CarboMIP arm), because of loss
of follow up (n = 3), incomplete assessment work-up (n = 1), major
protocol violation (n = 3), early death not reported as due to disease
or treatment toxicity (n = 16, including six sudden deaths), too long
a delay between two courses of therapy (n = 1), chemotherapy
discontinuation for intercurrent disease (n = 2), patient’s refusal of
further treatment (n = 1), death before treatment (n = 2). Thus, 268
patients were assessable for response.
Characteristics of the eligible patients are listed in Table 1. Both
arms were well balanced for the main patients characteristics.
There were 147 patients on the MIP arm and 150 on the CarboMIP
arm. The majority of the patients were male (83%) and had a good
Karnofsky PS (≥ 80 in 67%). Only eight (3%) presented with stage
IIIB disease and malignant pleural effusion and 18 (6%) had
undergone prior chest irradiation. Histology was adenocarcinoma
in 47.5% and squamous cell carcinoma in 33.3%. Twenty seven
percent of the patients had brain metastases.
The median follow-up duration was 96 weeks (range, 1–168).
At the time of the present analysis, 261 patients were dead, 36
were alive, and two had been lost to follow-up evaluation.
Tumour response
As shown in Table 2, there was a 27% (95% CI, 19–34) OR rate to
MIP (25% of eligible patients; 95% CI, 17–32) and a 33% (95%
CI, 24–41) OR rate to CarboMIP (29% of the eligible patients;
95% CI, 21–36). This difference was not statistically significant
(P = 0.34). In none of subgroups of patients with a similar charac-
teristic (age, sex, weight-loss, PS, type of lesion, histology, pres-
ence of brain metastases, prior surgery or radiotherapy) was there
a significant difference in response rates between the two arms.
By univariate analysis performed on all eligible patients (Table
3), six variables were found to be significant prognostic factors
for a higher response rate: squamous cell carcinoma, absence of
brain metastases, normal serum alkaline phosphatases, no prior
local treatment, a lower serum creatinine level and a Karnofsky
PS > 70.
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Table 1 Patient characteristics
Treatment arm
MIP CarboMIP
Eligible patients (n) 147 150
Sex
male 116 130
Female 31 20
Age in years
Median 61 62
Range 32–78 34–75
Karnofsky PS
≤ 70 48 50
≥ 80 99 100
Type of lesions
Assessable 70 77
Measurable 77 73
Loss of body weight
< 5% 84 82
≥ 5% 52 60
Unknown 11 8
Histology
Squamous cell carcinoma 42 57
Adenocarcinoma 75 66
Other non-small-cell 30 27
Disease extent
Stage IIIB 4 4
Stage IV 143 146
Brain metastases (n)4 2 3 7
Prior chest irradiation (n)1 1 7
Prior surgery (n)1 3 1 8A multivariate analysis with data fitted using logistic regression
model selected with a backward stepwise method was performed.
The potential covariates were all of the aforementioned significant
ones plus neutrophil count in a subset of 270 assessable patients
who had all data available. Significant independent factors identi-
fied were histology (P = 0.001), prior local treatment (P = 0.01),
brain metastases (P = 0.01), serum alkaline phosphatases (P =
0.02) and Karnofsky PS (P = 0.05). Increased odds ratios for a
higher OR rate were 1.90 (95% CI, 1.00–3.69) for PS > 70 and
2.08 (95% CI, 1.09–3.96) for increased alkaline phosphatases.
Decreased odds ratios for a lower OR rate were 0.33 (95% CI,
0.17–0.62) for adenocarcinoma and 0.35 (95% CI, 0.16–0.81) for
other NSCLC subtypes, 0.41 (95% CI, 0.19–0.86) for the presence
of brain metastases and 0.22 (95% CI, 0.06–0.77) for prior local
treatment.
Duration of response
Duration of response was not significantly different between the
arms, with a median of 23 weeks (95% CI, 21–29) for MIP and
30 weeks (95% CI, 24–36) for CarboMIP. The progression-free
survival was also not significantly different between both treat-
ments.
Survival
There was no difference (P = 0.67) in survival between the study
arms (Figure 1): median survival times were 28 weeks (95% CI,
24–32) for MIP and 32 weeks (95% CI, 26–35) for CarboMIP with
respectively 1-year survival rates of 24% and 23% and 2-year
survival rates of 5% and 2%. At time of analysis, 134 deaths were
observed in the MIP arm and 129 in the CarboMIP arm. In no
subgroup defined by a clinical characteristic (age, sex, PS, weight-
loss, type of lesions, histology, brain metastases, prior local
therapy) was a statistically significant difference found for
survival, according to regimen.
Some variables were identified by univariate analysis (Table
3) as significantly associated with improved survival: female
sex, PS ≥ 80, body weight-loss ≤ 5%, prior local therapy, normal
white blood cells, normal neutrophil count, normal haemoglobin
level, normal alkaline phosphatases, normal LDH level and
serum creatinine ≥ 1 mg dl–1. A Cox model, using all variables
with a P-value < 0.3 in univariate analysis (except LDH and
weight-loss), performed in 270 patients for which the data were
available, selected as significant independent factors for
survival: sex (HR 0.62 in favour of female; 95% CI, 0.43–0.90; P
= 0.008), PS (HR 0.60 in favour of PS > 70; 95% CI, 0.45–0.78;
P < 0.001), prior local therapy (HR 0.57 in favour of prior treat-
ment; 95% CI, 0.37–0.88; P = 0.006) and neutrophils (HR 1.73
in favour of normal count; 95% CI, 1.32–2.28; P < 0.001). When
performed on a restricted set of 211 patients for which LDH and
weight-loss data were available, the same factors were found as
significant, except sex that was not anymore selected and
histology that was an independent predictor in favour of adeno-
carcinoma.
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Table 2 Evaluation of response
Results Treatment arm
MIP CarboMIP
Patients (n) 147 150
Not assessable for response (n)1 1 1 8
Assessable for response (n) 136 132
PR (n)3 6 4 3
OR rate (%) 27 33
NC (n)4 5 3 9
PG (n)4 3 3 0
ED due to cancer (n)7 4
Toxic death (n)2 5
Removal because of excessive toxicity (n)3 1 0
Death by tumoural necrosis (n)0 1
PR = partial response; OR = objective response; NC = no change;
PG = progression; ED = early death
Table 3 Univariate prognostic factors analysis
Factor Response P Median survival P
(%) (weeks)
Treatment
MIP 25 28
CarboMIP 29 0.34 32 0.67
Age
< 60 years 24 30
≥ 60 years 28 0.53 29 0.87
Sex
Male 27 29
Female 26 0.98 37 0.02
Weight-loss
≤ 5% 30 35
> 5% 24 0.39 24 0.002
Karnofsky PS
≤ 70 17 20
≥ 80 31 0.02 35 < 0.001
Lesion type
Assessable 26 32
Measurable 27 0.87 28 0.49
Histology
Squamous cell carcinoma 41 30
Adenocarcinoma 18 33
Other types of NSCLC 23 < 0.001 24 0.09
Brain metastases
Absent 31 32
Present 14 0.005 24 0.06
Prior surgery or radiotherapy
No 29 29
Yes 8 0.01 50 0.003
WBC (per mm3)
≤ 10 000 29 37
> 10 000 24 0.39 23 < 0.001
Neutrophils (per mm3)
≤ 7500 30 37
> 7500 22 0.14 18 < 0.001
Platelets (per mm3)
≤ 440 000 27 31
> 440 000 26 1 26 0.19
Haemoglobinaemia (g dl–1)
12–18 29 33
< 12 or > 18 22 0.31 21 0.002
Alkaline phosphatases (mU ml–1)
≤ 110 17 35
> 110 33 0.006 28 0.04
LDH (mU ml–1)
≤ 200 23 37
> 200 29 0.40 28 0.02
Serum creatinine (mg dl–1)
≤ 12 5 2 8
> 1 35 0.25 41 0.03Toxicity
As summarized in Table 4, the main toxicities consisted in emesis,
alopecia, leucopenia and thrombocytopenia. Except alopecia,
those events were significantly more severe on the CarboMIP arm.
Chronic auditory, renal and neurological toxicity were infrequent
and the risk of developing at least one grade II–IV of one of these
toxicities was not significantly different between the two study
arms (6% vs 8% after three courses and 9% vs 11% after six
courses, respectively, for MIP and CarboMIP). There were seven
toxic deaths: two on the MIP arm (all febrile neutropenia) and five
on the CarboMIP arm (three febrile neutropenia, one acute renal
failure and one cerebral stroke).
Dose intensity
Median (range) cumulative doses of drugs per patient, for the MIP
and CarboMIP arms respectively, were: 151 (49–313) and 361
(0–733) mg m–2 for platinum derivatives (in cisplatinum-
equivalent), 18 (5.6–37.5) and 18.2 (0–36.9) mg m–2 for mito-
mycin (P = 0.16) and 9.0 (2.8–18.9) and 9.1 (0–22.2) g m–2 for
ifosfamide (P = 0.30). Median absolute dose-intensity was,
respectively for patients treated respectively by MIP and
CarboMIP, 15.9 (9.1–19.9) and 34.4 (0–41.8) mg m–2 wk–1 for plat-
inum derivatives, 1.9 (0.9–2.1) and 1.7 (0–2.1) mg m–2 wk–1 for
mitomycin (P < 0.001) and 0.95 (0.33–1.13) and 0.88 (0–1.35) g
m–2 wk–1 for ifosfamide (P < 0.001).
The potential influence of the modality of prescription of carbo-
platin was retrospectively evaluated by calculating the carboplatin
dosing according to the Calvert AUC-based equation and the
glomerular filtration rate (GFR) by the Cockcroft and Chatelut
methods. There was a good linear relationship between the results
obtained by both methods. For the first course of chemotherapy,
the median AUC given was retrospectively calculated to be 3.6 for
the two methods. Nineteen per cent of the patients had received an
AUC < 3 using the Cockcroft equation compared with 20% using
the Chatelut method. Haematological toxicity did not appear to be
significantly associated with the AUC administered, except for
course 1 and grade III/IV leucopenia (15% toxicity if AUC < 3 vs
44% if AUC ≥ 3; P = 0.01).
DISCUSSION
The principal finding of this trial, conducted in metastatic NSCLC,
was the lack of improvement in terms of response rate and survival
when a combination of moderate dosage cisplatin (60 mg m–2) and
carboplatin (200 mg m–2) was substituted for moderate dosage
cisplatin (50 mg m–2) in a mitomycin–ifosfamide chemotherapy
regimen. Our Group confirms, in some ways, the data reported in
one of its previous trials (Klastersky et al, 1986) showing no
significant change of response rate and survival when, in an etopo-
side containing regimen, 120 mg m–2 cisplatin was compared to
60 mg m–2 cisplatin in advanced NSCLC. In fact, none of the
randomized trials testing the role of the dosage of cisplatin have so
far reported significant differences (Gralla et al, 1984, Klastersky
et al, 1986; Shinkai et al, 1986; Gandara et al, 1993). The only
argument for a high dosage is based on a meta-analysis, conducted
in the early nineties (Donnadieu et al, 1991), where we compared
regimens with a ‘low’ dose (≤ 70 mg m–2) to those with a ‘high’
dose (≥ 100 mg m–2). Response rate was significantly higher (P =
0.005) with high-dose regimens (34% or 278/819 patients) than
with low-dose regimens (28% or 699/2497). In the present trial,
we observed a similar difference in response rate (27 vs 33%);
however, to detect such a theoretical difference (α = 5%, β =
20%), a much larger accrual of patients would have been required
(about 1000 per arm). Nevertheless, response rate is much less
important than survival and as the survival curves were strictly
superimposed, it is very unlikely that a benefit for the patient has
been missed.
We have not used high-dose cisplatin for the ‘high-dose’ arm,
but a combination of moderate dosages of cisplatin (60 mg m–2)
and carboplatin (200 mg m–2). This approach is based on the find-
ings of our two recent studies performed in metastatic NSCLC
(Sculier et al, 1994a; 1998) showing that regimens combining
moderate-dose cisplatin and carboplatin are as active as high-dose
cisplatin alone, but with significantly less chronic toxicity. The
present study confirms the low rate of occurrence of renal failure,
ototoxicity or polyneuropathy with this platinum derivatives com-
bination.
As the addition of carboplatin to a moderate dose of cisplatin
fails to produce a significant survival advantage, a further question
would be to determine if cisplatin might be replaced by carbo-
platin alone (given at 200 mg m–2 or AUC 3–4). The potential
advantage of that substitution would be easier chemotherapy
administration but at the probable cost of greater haematological
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Figure 1 Survival according to treatment
Table 4 Main toxicities for the first three courses per patient per arm
Toxicity Treatment arm P
MIP CarboMIP
Acute (% grade III–IV)
Emesis 4 12 0.04
Alopecia 17 26 0.11
Leucopenia 35 65 < 0.001
Infection 9 9 1
Thrombocytopenia 14 54 < 0.001
Bleeding 0 1 0.24
Chronic (% grade II–IV)
Auditory 0 0 1
Renal 0 5 0.008
Neurological 7 5 0.40
At least one of these 6 8 0.68Cisplatin, carboplatin, mitomycin and ifosfamide in NSCLC 1133
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toxicity. A trial testing this question would in fact be the counter-
part at a lower dosage level of another study of our Group
(Klastersky et al, 1990), that compared both drugs at higher
dosages in combination with etoposide, with a better response rate
for cisplatin but without significant survival difference.
In our previous trial (Sculier et al, 1998), a retrospective
analysis has shown (Sculier et al, 1999b) that the therapeutic index
was improved when the carboplatin dosage was calculated
according to the AUC, because of significantly lower haemato-
logical toxicity. The data of the present trial that includes a much
smaller number of patients assessable for that question are never-
theless consistent with the above-mentioned analysis, a greater
rate of leucopenia being observed with higher AUC. This observa-
tion has led our Group to prescribe, for further trials, carboplatin
using the Calvert formula.
The choice of drugs that we used was mainly based on the publi-
cation of Cullen et al (1988). We have shown in the above-
mentioned previous trial (Sculier et al, 1998) that the addition of
ifosfamide to moderate-dose cisplatin and carboplatin very signi-
ficantly improves the tumour response rate. Despite the fact that
there was no apparent effect on survival in the study, as it is usual
in trials adding other active drugs except vinorelbine to platinum
(Klastersky et al, 1989; Kawahara et al, 1991; Wozniak et al,
1998), ifosfamide can be considered as having a positive effect.
The role of mitomycin C nevertheless might be more controversial
because none of the eight randomized trials testing the addition of
this drug to a cisplatin-based regimen has shown a significant
survival advantage (Einhorn et al, 1986; Bonomi et al, 1989; Crino
et al, 1990; Fukuoka et al, 1991; Shinkai et al, 1991; Weick et al,
1991; Mylonakis et al, 1992; Gandara et al, 1993). Only two trials
have shown an improvement in the response rate and actually they
could be criticized: in the first (Bonomi et al, 1989), a lower dose
of cisplatin was used in the arm with mitomycin and in the second
(Gandara et al, 1993), an unusually very high dosage of cisplatin
was administered (200 mg m–2). For all these reasons, it is very
doubtful that mitomycin played a clinically significant role in our
study and our Group has decided not to use this drug in further
trials.
The analysis of dose-intensity might provide a potential expla-
nation for the absence of survival difference between both arms.
Indeed in the CarboMIP arm, there was a significant absolute
dose-intensity reduction for ifosfamide and mitomycin, as a result
of more frequent dose reductions and treatment delays due to
increased haematological toxicity, probably related to the adminis-
tration of carboplatin. The potential benefit of a higher dose-
intensity in platinum derivatives might thus have been cancelled
by the lower ones of the two other drugs in this arm. A similar
observation was made in the trial where we tested the role of the
addition of ifosfamide to the platinum derivatives combination
(Sculier et al, 1998).
The prognostic factor analysis has provided some new data in
comparison to our prior experience (Sculier et al, 1994b; 1998;
Paesmans et al, 1995; 1997; Borges et al, 1996). Prior local treat-
ment (surgery and/or chest irradiation) has been found to be an
independent predictor of poor response to chemotherapy but it
predicted better survival. A potential explanation might be cancer
growing more slowly. This observation is new because to the best
of our knowledge, it has never been reported before in multivariate
analysis, even in our recently published trial performed on
exactly the same type of patients (Paesmans and Sculier, 1998).
Nevertheless, in this latter, chemotherapy regimen was a very
significant prognostic factor for response, contrary to the present
trial. The adenocarcinoma histological subtype was a highly
significant predictor for poor response to chemotherapy, as we
have also observed in our previous studies (Borges et al, 1996;
Sculier et al, 1998). Patients with brain metastases had also less
frequently an objective response. Although these characteristics
have no significant impact on survival, their effect on response-
rate might be an explanation for the discrepancies observed
between series of patients with the same criteria of selection and
treated with the same regimen, but with an accrual of patients with
different characteristics. We found, as we had previously in older
studies, a better prognosis for survival in female (Paesmans
et al, 1995) and in patients with non-increased neutrophil counts
(Paesmans et al, 1995; Sculier et al, 1998). This latter factor,
although rarely investigated by other groups, is consistently
present in all our analyses performed in lung cancer patients. It
may be related to the absence of infection and/or of paraneoplastic
production of hormones or cytokines.
Finally, new active drugs have recently become available for the
treatment of NSCLC and it can be argued that the regimens that we
have studied are today obsolete. In fact, the available randomized
trials directly comparing regimens with new drugs (the ‘second
generation’) to regimens with older drugs (the ‘first generation’)
have so far not shown an advantage in terms of survival for the
new drugs (Giaccone et al, 1998; Crino et al, 1999), although some
benefits in terms of response rate or quality of life have been
reported. Moreover, the MIP regimen is considered in Europe as
one of the standard chemotherapies for NSCLC (Crino et al, 1990;
Cullen et al, 1999).
In conclusion, our trial fails to demonstrate a significant
improvement in response rate or survival when patients with
metastatic NSCLC are treated, with the addition to ifosfamide
and mitomycin, by combination of moderate dosages of cisplatin
(60 mg m–2) and carboplatin (200 mg m–2) instead of moderate
dosage cisplatin (50 mg m–2) alone. The results support the use of
a moderate dose of cisplatin for the chemotherapy of this disease.
The purpose of our next trial will be to compare, in this type of
patient, regimens with or without cisplatin.
REFERENCES
Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B,
Hahn R, Tormey DC, Harris J, Comis R and Glick J (1989) Combination
chemotherapy versus single agents followed by combination chemotherapy in
stage iv non-small-cell lung cancer: a study of the Eastern Cooperative
Oncology Group. J Clin Oncol 7: 1602–1613
Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, Lecomte J,
Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergysels R,
Mommen P and Klastersky J (1996) Prognostic factors for response to
chemotherapy containing platinum derivatives in patients with unresectable
non-small cell lung cancer (NSCLC). Lung Cancer 16: 21–33
Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A,
Bianco R, Marangolo M, Di Constanzo F, Sassi M, Barni S, Ravaioli A,
Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F and
Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and
cisplatin in advanced non-small-cell lung cancer: A randomized phase III study
of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–3530
Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Constanzo F, Buzzi F,
Fornari G, Santi E, Ballatori E, Santucci C and Davis S (1990) A randomized
trial of three cisplatin-containing regimens in advanced non-small-cell lung
cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer
Chemother Pharmacol 26: 52–56Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi
R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK,
Tobias J and Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in
unresectable non-small-cell lung cancer: effects on survival and quality of life.
J Clin Oncol 17: 3188–3194
Cullen MH, Joshi R, Chetiyawardana AD and Woodroffe CM (1988) Mitomycin,
ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough
to compare. Br J Cancer 58: 359–361
Depierre A, Chastang CI, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E,
Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM,
Cordier JF, Salal-Celigny P, Badri N and Benseval M (1994) Vinorelbine
versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a
randomized trial. Ann Oncol 5: 37–42
Donnadieu N, Paesmans M and Sculier JP (1991) Chimiothérapie des cancers
bronchiques non à petites cellules. Méta-analyse de la littérature en fonction de
l’extension de la maladie. Rev Mal Resp 8: 197–204
Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn,
Drasga R, Songer J, Fisher W, Stephens D and Hui S (1986) Random
prospective study of vindesine versus vindesine plus high-dose cisplatin versus
vindesine plus cisplatine plus mitomycin C in advanced non-small-cell lung
cancer. J Clin Oncol 4: 1037–1043
Elliott JA, Ahmedzai S, Hole D, Dorward AJ, Stevenson RD, Kaye SB, Banham
SW, Stack BHR and Calman KC (1984) Vindesine and cisplatin combination
chemotherapy compared with vindesine as a single agent in the management of
non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 20:
1025–1032
Fuks JZ, Aisner J, Van Echo DA, Schipper H, Levitt M, Ostrow S and Wiernik Ph
(1983) Randomized study of cyclophosphamide, doxorubicin, and etoposide
(VP16–213) with or without cisplatinum in non-small cell lung cancer. J Clin
Oncol 1: 295–301
Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N,
Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M and
Kusunoki Y (1991) A randomized trial in inoperable non-small-cell lung
cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin
versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin
Oncol 9: 606–613
Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR,
Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB and Balcerzak P
(1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung
cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11:
873–878.
Giaccone G, Splinter TA and Debruyne C (1998) Randomized study of paclitaxel-
cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell
lung cancer. The European Organization for Research and Treatment of Cancer
Lung Cancer Cooperative Group J Clin Oncol 16: 2133–2141
Gralla RJ, Casper ES, Kelsen DP, Braun DP, Dukeman ME, Martini N, Young CW,
and Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for
advanced carcinoma of the lung: a randomized trial investigating two dosage
schedules. Ann Intern Med 95: 414–420
Grilli R, Andrew D, Oxman AD and Julian JA (1993) Chemotherapy for advanced
non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:
1866–1872
Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N and Rapp E (1990)
Counting the costs of chemotherapy in a National Cancer Institute of Canada
randomized trial in non small-cell lung cancer. J Clin Oncol 8: 1301–1309
Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, Negoro S,
Kusunoki Y, Matui K and Takifuji N (1991) A randomized study of cisplatin
versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68:
714–719
Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J,
Lecomte J, Cordier R, Dabouis G, Brohée D, Thémelin L and Mommen P for
the Lung Cancer Working Party (1989) Cisplatin versus cisplatin plus
etoposide in the treatment of advanced non-small-cell lung cancer. J Clin
Oncol 7: 1087–1092
Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M,
Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC,
Sergysels R, Mommen P and Paesmans M (1990) A randomized study
comparing cisplatin or carboplatin with etoposide in patients with advanced
non-small-cell lung cancer: European Organization for Research and Treatment
of Cancer protocol 07861. J Clin Oncol 8: 1556–1562
Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P,
Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P and Dalesio O
and the EORTC Lung Cancer Working Party (1986) A randomized study
comparing a high and a standard dose of cisplatin in combination with
etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin
Oncol 4: 1780–1786.
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Rivière
A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard
MH, Ravaiolo A, Benseval M, Besson F, Martinez A, Berthaud P and Tursz T
(1994) Randomized study of vinorelbine and cisplatin versus vindesine and
cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer:
results of a European multicenter trial including 612 patients. J Clin Oncol 12:
360–367
Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R and Greco
FA (1990) Randomized comparison of two combination regimens versus
minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer
Study Group trial. J Clin Oncol 8: 886–891
Marino P, Pampallona S, Preatoni A, Cantoni A and Invernizzi F (1994)
Chemotherapy vs supportive care in advanced non-small cell lung cancer.
Results of a meta-analysis of the literature. Chest 106: 861–865
Meert AP, Berghmans T, Branle F, Lemaitre F, Mascaux C, Rubesova E, Vermylen P,
Paesmans M and Sculier JP (1999) Phase II and III studies with new drugs for
non-small cell lung cancer. A systematic review of the literature with a
methodology quality assessment. Anticancer Res 19: 4379–4390
Mylonakis N, Tsavaris N, Bacoyiannis C, Karvounis N, Kakolyris S, Karabelis A,
Beer M and Kosmidis P (1992) A randomized prospective study of cisplatin
and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-
small cell lung cancer. Ann Oncol 3: 127–130
Paesmans M and Sculier JP (1998) Facteurs pronostiques des cancers
bronchopulmonaries. In Cancers Bronchopulmonaires, Milleron B and
Depierre A (eds) pp. 239–247. Vélizy-Villacoublay: Arnette
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van
Cutsem O, Sergysels R, Mommen P and Klastersky J for the European Lung
Cancer Working Party (1995) Prognostic factors for survival in advanced non
small cell lung cancer; uni and multivariate analyses including recpam analysis
in 1052 patients. J Clin Oncol 13: 1221–1230
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van
Cutsem O, Sergysels R, Mommen P and Klastersky J for the European Lung
Cancer Working Party (1997) Response to chemotherapy has a discriminant
value on the distribution of further survival for patients with advanced non
small cell lung cancer: a ten years experience of the European Lung Cancer
Working Party. Eur J Cancer 33: 2326–2332
Robert F, Omura GA, Birch R, Krauss S and Oldham R (1984) Randomized phase
III comparison of three doxorubicin-based chemotherapy regimens in advanced
non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin
Oncol 2: 391–395
Rosso R, Salvati F, Ardizzoni A, Curcio CG, Rubagotti A, Belli M, Castagneto B,
Fusco V, Sassi M, Ferrara G, Pizza A, Pedicini T, Soresi E, Scoditti S, Cioffi R,
Folco U, Monaco M, Merlano M, Rimoldi R, Tonachella R, Cruciani A,
Colantuoni G, Rinaldi M, Portalone L, Bruzzi P and Santi L (1990) Etoposide
versus etoposide plus high-dose cisplatin in the management of advanced non-
small cell lung cancer. Cancer 66: 130–134
Sculier JP, Berghmans T, Castaigne C, Lalami Y, Luce S, Sotiriou C, Vermylen P
and Paesmans M (1999a) Best supportive care or chemotherapy for stage IV
non small cell lung cancer. In Progress and Perspectives in Lung Cancer. Van
Houtte P, Klastersky J and Rocmans P (eds) pp. 199–207. Berlin: Springer
Verlag
Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, Efremidis A,
Ries F, Berchier MC, Sergysels R, Mommen P and Paesmans M for the
European Lung Cancer Working Party (1994a) Phase II randomized trial
comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in
patients with advanced non-small-cell lung cancer. J Clin Oncol 12: 353–359
Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, Berchier MC, Van
Cutsem O, Küstner U, Kroll F, Sergysels R, Mommen P and Klastersky J for
the European Lung Cancer Working Party (1996) A randomized trial
comparing induction chemotherapy versus induction chemotherapy followed
by maintenance chemotherapy in small cell lung cancer. J Clin Oncol 14:
2337–2344
Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van
Cutsem O, Schmerber J, Giner V, Berchier MC, Sergyselq R, Mommen P and
Klastersky J for the European Lung Cancer Working Party (1994b) Long-term
survival after chemotherapy containing platinum derivatives in patients with
advanced unresectable non small cell lung cancer. Eur J Cancer 30A:
1342–1347
Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A,
Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V,
Klastersky J and the European Lung Cancer Working Party (1998) Phase III
randomized trial comparing cisplatin and carboplatin with or without
1134 J-P Sculier et al
British Journal of Cancer (2000) 83(9), 1128–1135 © 2000 Cancer Research CampaignCisplatin, carboplatin, mitomycin and ifosfamide in NSCLC 1135
British Journal of Cancer (2000) 83(9), 1128–1135 © 2000 Cancer Research Campaign
ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol
16: 1388–1396
Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Koumakis G,
Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V,
Klastersky J and the European Lung Cancer Working Party (1999b) A
comparison of methods of calculation for estimating carboplatin AUC with a
retrospective pharmacokinetic–pharmacodynamic analysis in patients with
advanced non-small cell lung cancer. Eur J Cancer 35: 1314–1319
Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F and Saijo N
(1991) A randomized clinical trial of vindesine plus cisplatin versus mitomycin
plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J
Cancer 27: 571–575
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M, Suga J, Miyoaka
H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A and Jett JR
(1986) Cisplatin and vindesine combination chemotherapy for non-small cell
lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J
Cancer Res 77: 782–789
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Comier Y, Ganz A, Kaasa S, Pater
JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL and Bernard JP
(1993) Polychemotherapy in advanced non-small-cell lung cancer: a meta-
analysis. Lancet 342: 19–21
Thongprasert S, Sanguanmitra P, Juthapan W and Clinch J (1999) Relationship
between quality of life and clinical outcomes in advanced non-small cell lung
cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung
Cancer 24: 17–24
Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CA, Taylor SA and
Livingston RB (1991) A randomized trial of five cisplatin-containing
treatments in patients with metastatic non-small-cell lung cancer: a Southwest
Oncology Group Study. J Clin Oncol 9: 1157–1162
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH,
Albain KS, Kelly K, Taylor SA, Gandara DR and Livingston RB (1998)
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the
treatment of advanced non-small-cell lung cancer: a Southwest Oncology
Group study. J Clin Oncol 16: 2459–2465
APPENDIX
European Lung Cancer Working Party participating
institutions, with investigators:
Institut Jules Bordet, Brussels, Belgium
JP Sculier
T Berghmans
P Van Houtte
J Klastersky
M Paesmans
P Mommen
Hôpital Saint-Pierre, Brussels, Belgium
V Ninane
T Bosschaerts
R Sergysels
Hôpital Albert Calmette, Lille, France
JJ Lafitte
CHV de Charleroi, Charleroi, Belgium
J Thiriaux
J Lecomte
A Wattiez
Evangelismos General Hospital, Athens, Greece
CG Alexopoulos
M Vaslamatzis
Klinika Radiotherapie a Onkologie, Kosice, Slovakia
J Baumöhl
Hôpital Brugmann, Brussels, Belgium
A Drowart
T Prigogine
Hellenic Cancer Institute, Athens, Greece
A Efremidis
G Koumakis
CH de Douai, Douai, France
MC Florin
E Maetz
CHI de Montfermeil, Montfermeil, France
C Zacharias
Hôpital Ambroise Paré, Mons, Belgium
P Recloux
Hospital de Sagunto, Valencia, Spain
V Giner
CH de Roubaix, Roubaix, France
F Kroll
F Steenhouwer
A Strecker
Hôpital d’Hayange, Hayange, France
MC Berchier
Clinique Saint-Luc, Namur, Belgium
O Van Cutsem
M Mairesse
Clinique Louis Caty, Baudour, Belgium
V Richard
D Diana
CHU A Vésale, Montigny-le-Tilleul, Belgium
D Brohée
Hôpital de Warquignies, Boussu, Belgium
P Libert
M Richez
CH Peltzer-La Tourelle, Verviers, Belgium
JL Corhay
CHG de Tourcoing, Tourcoing, France
X Ficheroulle
Hôpital de la Madeleine, Ath, Belgium
P Ravez
Hôpital de Braine-l’Alleud, Braine-l’Alleud, Belgium
C Finet
Cabinet Médical de Dampierre, Anzin, France
B Stach
JP Roux
Clinique de La Louvière, Lille, France
F Fortin
JM Dernis
JM Grosbois
IMC Mutualités Socialistes, Tournai, Belgium
A Tagnon
G Nuttin
Centre Hospitalier Dr Schaffner, Lens, France
J Amourette
Hôpital Duchenne, Boulogne sur Mer, France
JL Crépin
Cabinet de Pneumologie, Tourcoing, France
Y Watrigant